查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1968564

兽用单株抗体市场－全球产业规模、份额、趋势、机会和预测：按动物类型、应用、最终用户、地区和竞争对手划分，2021-2031年

Monoclonal Antibodies In Veterinary Health Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Animal Type, By Application, End-User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球兽用单株抗体市场预计将从 2025 年的 9.2412 亿美元成长到 2031 年的 22.0648 亿美元，复合年增长率为 15.61%。

这些专门的生物疗法旨在靶向疾病路径中的特定蛋白质，例如受体和细胞激素，用于治疗动物的皮肤炎、癌症和骨关节炎等疾病。推动该市场成长要素是宠物慢性病发病率的上升以及宠物照护方式日益趋向人类化。这促使人们对副作用比传统药物更少的、高度先进且具有物种特异性的治疗方法的需求不断增长。根据美国兽医协会 (AVMA) 预测，到 2025 年，美国犬隻数量将达到 8,730 万隻，这意味着这些疗法的患者群体正在扩大。

市场概览
预测期 2027-2031
市场规模：2025年 9.2412亿美元
市场规模：2031年 22.0648亿美元
复合年增长率：2026-2031年 15.61%
成长最快的细分市场 皮肤科
最大的市场 北美洲

儘管生物製药市场成长潜力巨大，但由于其研发和生产高成本，仍面临严峻的挑战。不断上涨的生产成本最终导致宠物饲主需要支付更高的价格，从而限制了低收入社区和价格敏感地区的宠物获得和使用。因此，儘管单株抗体的临床优势显而易见，但经济负担仍是其在全球市场渗透的主要障碍。

市场驱动因素

动物慢性疾病和感染疾病率的上升是推动单株抗体应用的主要动力，尤其是在骨关节炎等疾病的长期疼痛管理方面。传统的非类固醇消炎剂（NSAIDs）长期使用会产生副作用，而单株抗体透过中和特定蛋白，在提供镇痛效果的同时，具有更高的安全性。这一转变在硕腾公司（Zoetis Inc.）2025年2月发布的财报中得到了印证，该财报显示其骨关节炎疼痛管理业务部门实现了80%的业务增长，这证实了兽医越来越倾向于优先采用生物製药疗法治疗老年宠物的慢性疾病。

同时，宠物健康保险的日益普及在维持市场成长方面发挥着至关重要的作用，它能够抵消这些先进疗法的高成本。由于单株抗体价格昂贵，保险覆盖确保了患者坚持治疗并获得广泛的治疗机会。美国宠物用品协会 (APPA) 2025 年 3 月的数据显示，饲主愿意在医疗保健方面投入资金，数据显示，2024 年美国宠物产业的支出将达到 1,520 亿美元。此外，北美宠物健康保险协会 (NAPHIA) 2025 年 6 月的报告显示，2024 年美国宠物健康保险的总保费收入将超过 47 亿美元的历史新高，这表明市场对高价值兽医服务的强劲支持。

市场挑战

生物製药研发生产的高成本是限制全球兽用单株抗体市场扩张的主要经济障碍。由于这些治疗方法需要复杂的技术和生产过程，其高昂的价格往往会转嫁给消费者。因此，临床效用与实际可近性之间存在差距，兽医常常不愿意为经济拮据的饲主开具有效但昂贵的治疗方法。结果，许多潜在客户被迫依赖价格较低的传统药物，导致这些先进生物製药的市场份额下降。

这种价格敏感度直接影响宠物就诊频率和高价值治疗方案的采用率。根据澳洲动物医学会2025年的调查，30%的犬饲主22%的猫饲主表示，减少就诊次数的主要原因是经济负担。这项数据凸显了一个重要的摩擦点，即经济限制阻碍了人们获得医疗保健服务。只要这些治疗方案对一般收入家庭来说仍然难以负担，市场就难以将疾病发生率的上升转化为可持续的收入成长。

市场趋势

市场正从骨关节炎和皮肤病领域向其他领域扩展，治疗范围也不断扩大。尤其值得一提的是，针对感染疾病的单株抗体研发取得了显着进展。研发人员正在检验能够中和病毒威胁的生物製药的有效性，为高致死性疾病提供标靶治疗，作为支持性治疗的替代方案。例如，在犬小病毒的治疗方面，已经建立了既能控制症状又能直接攻击病毒本身的治疗方法。 2024年10月，礼来动物保健公司（Elanco Animal Health）公布的数据显示，使用其专有的犬细小病毒单株抗体治疗的幼犬存活率达到了93%，这表明在降低死亡率方面取得了显着进展。

此外，随着大型製药企业寻求整合来自敏捷生物技术公司的新型生物製药平台，策略授权协议和联合开发伙伴关係正在增加。这些合作使市场领导能够绕过药物研发瓶颈，并获得诸如延长半衰期等专有技术。一个典型的例子是，Dekra Pharmaceuticals 于 2024 年 7 月以高达 5.2 亿美元的价格收购了 Invex，从而获得了一系列用于治疗伴侣动物慢性疾病的特异性单株抗体。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：兽用单株抗体的全球市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 动物种类（狗，其他）
    • 依应用领域（皮肤科、疼痛管理、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美兽用单株抗体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲兽用单株抗体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区兽用单株抗体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲兽用单株抗体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美兽用单株抗体市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球兽用单株抗体市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Virbac SA
  • Ceva Sante Animale SA
  • IDEXX Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Vetoquinol SA
  • Aratana Therapeutics, Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 17566

The Global Monoclonal Antibodies In Veterinary Health Market is projected to expand from USD 924.12 Million in 2025 to USD 2206.48 Million by 2031, registering a CAGR of 15.61%. These specialized biologic therapies are engineered to target specific proteins, such as receptors or cytokines, within disease pathways to treat animal conditions like dermatitis, cancer, and osteoarthritis. The market is primarily driven by the increasing prevalence of chronic diseases in pets and the trend toward pet humanization, which fuels demand for advanced, species-specific treatments with fewer side effects than traditional drugs. As noted by the American Veterinary Medical Association, the U.S. dog population reached 87.3 million in 2025, highlighting a growing patient base for these therapeutics.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 924.12 Million
Market Size 2031USD 2206.48 Million
CAGR 2026-203115.61%
Fastest Growing SegmentDermatology
Largest MarketNorth America

Despite the strong potential for growth, the market encounters significant challenges due to the high costs associated with developing and manufacturing biologic drugs. These steep production expenses result in higher prices for pet owners, which restricts accessibility and adoption in lower-income demographics or price-sensitive regions. Consequently, while the clinical advantages of monoclonal antibodies are clear, the financial burden remains a major obstacle to achieving widespread global market penetration.

Market Driver

The rising incidence of chronic and infectious diseases in animals acts as a primary catalyst for the adoption of monoclonal antibodies, especially for long-term pain management in conditions like osteoarthritis. Unlike traditional NSAIDs, which can cause adverse effects over time, monoclonal antibodies neutralize specific proteins to provide pain relief with a better safety profile. This shift is highlighted by Zoetis Inc.'s February 2025 financial results, which reported an 80% operational growth in their osteoarthritis pain franchise, confirming that veterinarians are increasingly prioritizing biologic interventions for chronic ailments in aging pets.

Simultaneously, the increasing penetration of pet health insurance plays a crucial role in sustaining market growth by offsetting the high costs of these advanced treatments. Since monoclonal antibodies are premium products, insurance coverage ensures patient adherence and broader accessibility. The willingness of owners to spend on healthcare is reflected in American Pet Products Association data from March 2025, showing U.S. pet industry expenditures reached $152 billion in 2024. Additionally, the North American Pet Health Insurance Association reported in June 2025 that gross written premiums in the U.S. surpassed a record $4.7 billion in 2024, demonstrating strong financial support for high-value veterinary care.

Market Challenge

The elevated costs associated with developing and manufacturing biologic drugs create a substantial economic barrier that limits the expansion of the Global Monoclonal Antibodies In Veterinary Health Market. Because these therapies require complex engineering and production, the premium pricing is typically passed on to the consumer. This leads to a discrepancy between clinical availability and practical accessibility, as veterinarians are often hesitant to prescribe effective but expensive treatments to clients with limited funds. As a result, many potential customers depend on lower-cost conventional pharmaceuticals, reducing the market share for these advanced biologics.

This price sensitivity directly affects veterinary visit frequency and the uptake of high-value treatments. According to Animal Medicines Australia in 2025, 30% of dog owners and 22% of cat owners who reduced their veterinary visits cited affordability as the primary reason. This data underscores a critical friction point where economic constraints prevent access to necessary healthcare. As long as these treatments remain financially out of reach for average-income households, the market will struggle to convert rising disease prevalence into sustained revenue growth.

Market Trends

The market is expanding its therapeutic focus beyond osteoarthritis and dermatology, with a notable surge in monoclonal antibodies targeting infectious diseases. Developers are validating biologics that neutralize viral threats, providing targeted alternatives to supportive care for high-mortality conditions. For example, treatments for canine parvovirus now combat the virus directly rather than just managing symptoms. In October 2024, Elanco Animal Health released data showing that 93% of puppies treated with their Canine Parvovirus Monoclonal Antibody survived, marking a significant improvement in reducing mortality rates.

In addition, strategic licensing and co-development partnerships are increasing as major pharmaceutical companies seek to integrate novel biologic platforms from agile biotech firms. These collaborations allow market leaders to bypass discovery bottlenecks and access proprietary technologies, such as half-life extension. A key example occurred in July 2024, when Dechra Pharmaceuticals agreed to acquire Invetx for up to $520 million, thereby gaining access to a pipeline of specialized monoclonal antibodies for chronic diseases in companion animals.

Key Market Players

  • Zoetis Inc.
  • Elanco Animal Health Incorporated
  • Boehringer Ingelheim Animal Health GmbH
  • Merck & Co., Inc.
  • Virbac S.A.
  • Ceva Sante Animale S.A.
  • IDEXX Laboratories, Inc.
  • Thermo Fisher Scientific Inc.
  • Vetoquinol S.A.
  • Aratana Therapeutics, Inc.

Report Scope

In this report, the Global Monoclonal Antibodies In Veterinary Health Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Monoclonal Antibodies In Veterinary Health Market, By Animal Type

  • Dogs
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Application

  • Dermatology
  • Pain
  • Others

Monoclonal Antibodies In Veterinary Health Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Monoclonal Antibodies In Veterinary Health Market.

Available Customizations:

Global Monoclonal Antibodies In Veterinary Health Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Monoclonal Antibodies In Veterinary Health Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Animal Type (Dogs, Others)
    • 5.2.2. By Application (Dermatology, Pain, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Animal Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Animal Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Monoclonal Antibodies In Veterinary Health Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Animal Type
        • 6.3.3.2.2. By Application

7. Europe Monoclonal Antibodies In Veterinary Health Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Animal Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Animal Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Animal Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Animal Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Animal Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Monoclonal Antibodies In Veterinary Health Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Animal Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Monoclonal Antibodies In Veterinary Health Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Animal Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Animal Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Animal Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Animal Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Animal Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Animal Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Monoclonal Antibodies In Veterinary Health Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Animal Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Animal Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Animal Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Monoclonal Antibodies In Veterinary Health Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Animal Type
        • 9.3.3.2.2. By Application

10. South America Monoclonal Antibodies In Veterinary Health Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Animal Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Animal Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Animal Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Monoclonal Antibodies In Veterinary Health Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Animal Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Monoclonal Antibodies In Veterinary Health Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zoetis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Elanco Animal Health Incorporated
  • 15.3. Boehringer Ingelheim Animal Health GmbH
  • 15.4. Merck & Co., Inc.
  • 15.5. Virbac S.A.
  • 15.6. Ceva Sante Animale S.A.
  • 15.7. IDEXX Laboratories, Inc.
  • 15.8. Thermo Fisher Scientific Inc.
  • 15.9. Vetoquinol S.A.
  • 15.10. Aratana Therapeutics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer